Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world.
| trading_symbol | registrant_name | time | price | change | percentage_change |
|---|---|---|---|---|---|
| ELAN | Elanco Animal Health Inc | 2026-03-03 18:26:39 | 25.31 | 0.43 | 1.73 |
| trading_symbol | central_index_key | registrant_name | isin_number | lei_number | ein_number | exchange | sic_code | sic_description | fiscal_year_end | state_of_incorporation | address_street | address_city | address_state | address_zip_code | address_country | address_country_code | phone_number | mailing_address | business_address | former_name | industry | founding_date | chief_executive_officer | number_of_employees | website | market_cap | shares_issued | shares_outstanding | description | update_time |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ELAN | 0001739104 | Elanco Animal Health Inc | US28414H1032 | 549300SHPNDCE059M934 | 825497352 | NYSE | 2834 | Pharmaceutical Preparations | 1231 | — | 450 ELANCO CIRCLE | INDIANAPOLIS | IN | 46221 | UNITED STATES | US | 877-352-6261 | 450 ELANCO CIRCLE, INDIANAPOLIS, IN, 46221 | 450 ELANCO CIRCLE, INDIANAPOLIS, IN, 46221 | — | Pharmaceutical (animal) | 1954 | Jeff Simmons | 10,200 | http://elanco.com | 7,000,000,000 | 496,975,154 | 497,168,077 | Elanco Animal Health Incorporated is an American pharmaceutical company which produces medicines and vaccinations for pets and livestock. Until 2019, the company was a subsidiary of Eli Lilly and Company, before being divested. It is the third-largest animal health company in the world. | 2026-02-26 16:00:36 |
| Fiscal Year | Market Cap | Change In Market Cap | Percentage Change In Market Cap | Shares Outstanding | Change In Shares Outstanding | Percentage Change In Shares Outstanding |
|---|---|---|---|---|---|---|
| 2025 | 7,000,000,000 | -100,000,000 | -1.4085 | 497,168,077 | 2,554,137 | 0.5164 |
| 2024 | 7,100,000,000 | 2,200,000,000 | 44.898 | 494,613,940 | 1,643,929 | 0.3335 |
| 2023 | 4,900,000,000 | -4,400,000,000 | -47.3118 | 492,970,011 | 1,426,510 | 0.2902 |
| Executive Name | Executive Position | Fiscal Year | Salary | Bonus | Stock Awards | Incentive Plan Compensation | Other Compensation | Total Compensation |
|---|---|---|---|---|---|---|---|---|
| Ellen De Brabander | Executive Vice President | 2024 | 753,048 | 0 | 2,031,537 | 581,730 | 37,115 | 3,913,932 |
| Ramiro Cabral | President, Executive Vice President | 2024 | 620,000 | 0 | 1,361,268 | 478,950 | 28,501 | 2,942,471 |
| Jeffrey Simmons | CEO, President | 2024 | 1,200,000 | 0 | 9,000,027 | 1,606,800 | 26,871 | 14,833,704 |
| Todd Young | Chief Financial Officer, Executive Vice President | 2024 | 694,000 | 0 | 2,111,279 | 571,856 | 28,471 | 4,109,361 |
| Timothy Bettington | Executive Vice President | 2024 | 642,000 | 0 | 1,050,029 | 462,882 | 28,471 | 2,533,389 |
| Fiscal Year | Employee Count |
|---|---|
| 2025 | 9,400 |
| 2024 | 9,000 |
| 2023 | 9,300 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Revenue | 4,715,000,000 | 4,439,000,000 | 4,417,000,000 |
| Cost Of Revenue | 2,122,000,000 | 2,003,000,000 | 1,931,000,000 |
| Gross Profit | 2,593,000,000 | 2,436,000,000 | — |
| Research And Development Expenses | 368,000,000 | 344,000,000 | 327,000,000 |
| General And Administrative Expenses | 1,430,000,000 | 1,314,000,000 | 1,285,000,000 |
| Operating Expenses | 2,045,000,000 | 3,951,000,000 | 5,612,000,000 |
| Operating Income | — | — | — |
| Net Income | -232,000,000 | 338,000,000 | -1,231,000,000 |
| Earnings Per Share Basic | -0.47 | 0.68 | -2.5 |
| Earnings Per Share Diluted | -0.47 | 0.68 | -2.5 |
| Weighted Average Shares Outstanding Basic | 496,400,000 | 494,000,000 | 492,300,000 |
| Weighted Average Shares Outstanding Diluted | 496,400,000 | 497,300,000 | 492,300,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Cash And Cash Equivalents | 545,000,000 | 468,000,000 | 352,000,000 |
| Marketable Securities Current | — | — | — |
| Accounts Receivable | 873,000,000 | 805,000,000 | 842,000,000 |
| Inventories | 1,737,000,000 | 1,574,000,000 | 1,735,000,000 |
| Non Trade Receivables | 113,000,000 | 121,000,000 | 149,000,000 |
| Other Assets Current | — | — | — |
| Total Assets Current | 3,458,000,000 | 3,215,000,000 | 3,407,000,000 |
| Marketable Securities Non Current | — | — | — |
| Property Plant And Equipment | — | 993,000,000 | 1,026,000,000 |
| Other Assets Non Current | 304,000,000 | 311,000,000 | 341,000,000 |
| Total Assets Non Current | 9,900,000,000 | 9,399,000,000 | 10,955,000,000 |
| Total Assets | 13,358,000,000 | 12,614,000,000 | 14,362,000,000 |
| Accounts Payable | 368,000,000 | 296,000,000 | 270,000,000 |
| Deferred Revenue | 416,000,000 | 332,000,000 | 367,000,000 |
| Short Term Debt | 74,000,000 | 44,000,000 | 38,000,000 |
| Other Liabilities Current | 533,000,000 | 466,000,000 | 409,000,000 |
| Total Liabilities Current | 1,597,000,000 | 1,315,000,000 | 1,241,000,000 |
| Long Term Debt | 3,762,000,000 | 4,321,000,000 | 5,774,000,000 |
| Other Liabilities Non Current | 427,000,000 | 302,000,000 | 411,000,000 |
| Total Liabilities Non Current | 5,214,000,000 | 5,203,000,000 | 6,898,000,000 |
| Total Liabilities | 6,811,000,000 | 6,518,000,000 | 8,139,000,000 |
| Common Stock | 0 | 0 | 0 |
| Retained Earnings | -2,182,000,000 | -1,950,000,000 | -2,288,000,000 |
| Accumulated Other Comprehensive Income | -141,000,000 | -771,000,000 | -266,000,000 |
| Total Shareholders Equity | 6,547,000,000 | 6,096,000,000 | 6,223,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Depreciation And Amortization | 680,000,000 | 662,000,000 | 694,000,000 |
| Share Based Compensation Expense | 68,000,000 | 55,000,000 | 46,000,000 |
| Other Non Cash Income Expense | — | — | — |
| Change In Accounts Receivable | 12,000,000 | -12,000,000 | 40,000,000 |
| Change In Inventories | 57,000,000 | -44,000,000 | 160,000,000 |
| Change In Non Trade Receivables | — | — | — |
| Change In Other Assets | -21,000,000 | -11,000,000 | 6,000,000 |
| Change In Accounts Payable | — | — | — |
| Change In Other Liabilities | — | — | 0 |
| Cash From Operating Activities | 560,000,000 | 541,000,000 | 271,000,000 |
| Purchases Of Marketable Securities | — | — | — |
| Sales Of Marketable Securities | — | — | — |
| Acquisition Of Property Plant And Equipment | 276,000,000 | 147,000,000 | 140,000,000 |
| Acquisition Of Business | 0 | 41,000,000 | 19,000,000 |
| Other Investing Activities | 12,000,000 | 0 | -4,000,000 |
| Cash From Investing Activities | -279,000,000 | 1,158,000,000 | -169,000,000 |
| Tax Withholding For Share Based Compensation | — | — | — |
| Payments Of Dividends | — | — | — |
| Issuance Of Common Stock | — | — | 0 |
| Repurchase Of Common Stock | — | — | — |
| Issuance Of Long Term Debt | 2,106,000,000 | 350,000,000 | — |
| Repayment Of Long Term Debt | 125,000,000 | 250,000,000 | 150,000,000 |
| Other Financing Activities | -2,000,000 | -17,000,000 | -6,000,000 |
| Cash From Financing Activities | -275,000,000 | -1,492,000,000 | -83,000,000 |
| Change In Cash | 77,000,000 | 116,000,000 | 7,000,000 |
| Cash At End Of Period | 545,000,000 | 468,000,000 | 352,000,000 |
| Income Taxes Paid | 225,000,000 | 140,000,000 | 95,000,000 |
| Interest Paid | 206,000,000 | 296,000,000 | 379,000,000 |
| Fiscal Year | 2025 | 2024 | 2023 |
|---|---|---|---|
| Earnings Per Share | -0.47 | 0.68 | -2.5 |
| Price To Earnings Ratio | -48.1489 | 17.8088 | -5.96 |
| Earnings Growth Rate | -169.1176 | -127.2 | 1,462.5 |
| Price Earnings To Growth Ratio | 0.2847 | -0.14 | -0.0041 |
| Book Value Per Share | 13.189 | 12.3401 | 12.6407 |
| Price To Book Ratio | 1.7158 | 0.9814 | 1.1787 |
| Ebitda | 673,000,000 | 1,140,000,000 | -165,000,000 |
| Enterprise Value | 14,524,532,000 | 9,879,340,000 | 12,795,270,000 |
| Dividend Yield | — | — | — |
| Dividend Payout Ratio | — | — | — |
| Debt To Equity Ratio | 0.5859 | 0.716 | 0.934 |
| Capital Expenditures | — | 629,000,000 | 721,000,000 |
| Free Cash Flow | — | -88,000,000 | -450,000,000 |
| Return On Equity | -0.0354 | 0.0554 | -0.1978 |
| One Year Beta | 1.2805 | 1.0337 | 1.9487 |
| Three Year Beta | 1.3841 | 1.1999 | 1.1418 |
| Five Year Beta | 1.165 | 1.0865 | 1.0731 |
| Insider Name | Relationship To Issuer | Transaction Date | Amount Of Securities | Acquired Or Disposed | Securities Owned Following Transaction |
|---|---|---|---|---|---|
| VanHimbergen Robert M | EVP and CFO | 2026-02-20 | 7 | A | 31 |
| Simmons Jeffrey N | Director, PRESIDENT, CEO AND DIRECTOR | 2026-02-20 | 110 | A | 19,179 |
| Modi Rajeev A. | — | 2026-02-20 | 56 | A | 7,651 |
| Modi Rajeev A. | — | 2026-02-06 | 56 | A | 7,594 |
| Simmons Jeffrey N | Director, PRESIDENT, CEO AND DIRECTOR | 2026-02-06 | 109 | A | 19,068 |
| Name Of Reporting Person | Type Of Reporting Person | Report Date | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Daniel S Sullivan | Senator | 2023-07-26 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Daniel S Sullivan | Senator | 2022-12-21 | Sale (Full) | 2022-11-30 | Joint | $1,001 - $15,000 |
| Name Of Reporting Person | Report Date | State | Transaction Type | Transaction Date | Owner Type | Amount |
|---|---|---|---|---|---|---|
| Valerie Hoyle | 2025-10-10 | OR04 | Sale | 2025-09-23 | Spouse | $1,001 - $15,000 |
| Daniel Goldman | 2023-04-17 | NY10 | Sale (Partial) | 2023-03-06 | — | $1,001 - $15,000 |
| Susie Lee | 2022-12-29 | NV03 | Sale | 2022-11-30 | Joint | $1,001 - $15,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $15,001 - $50,000 |
| Alan S. Lowenthal | 2019-09-01 | CA47 | Sale | 2019-08-20 | Spouse | $1,001 - $15,000 |
| Investor Name | Period Of Report | Market Value | Amount Of Securities | Price Per Security |
|---|---|---|---|---|
| Centiva Capital, LP | 2025-12-31 | 256,851 | 11,350 | 22.63 |
| PANAGORA ASSET MANAGEMENT INC | 2025-12-31 | 5,941,597 | 262,554 | 22.63 |
| VICTORY CAPITAL MANAGEMENT INC | 2025-12-31 | 5,136,806 | 226,991 | 22.63 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 2025-12-31 | 168,000 | 7,409 | 22.6751 |
| CITIGROUP INC | 2025-12-31 | 6,928,741 | 306,175 | 22.63 |
| Registrant Name | Period Of Report | Fund Name | Fund Symbol | Amount Of Units | Value In Usd | Percentage Value Compared To Assets |
|---|---|---|---|---|---|---|
| PIMCO Equity Series | 2025-12-31 | Class A | PMJAX | 64,884 | 1,468,324.92 | 0.0488 |
| PIMCO Equity Series | 2025-12-31 | I-2 | PMJPX | 64,884 | 1,468,324.92 | 0.0488 |
| PIMCO Equity Series | 2025-12-31 | Institutional Class | PMJIX | 64,884 | 1,468,324.92 | 0.0488 |
| PIMCO Equity Series | 2025-12-31 | PIMCO RAFI Dynamic Multi-Factor U.S. Equity ETF | MFUS | 1,283 | 29,034.29 | 0.0138 |
| RYDEX SERIES FUNDS | 2025-12-31 | Class C | RYDCX | 1,366 | 30,912.58 | 0.2267 |